Preliminary findings were presented at the 2025 ASCO Genitourinary Cancers Symposium. 2 Investigators reported that 71% of ...
First-line treatment selection in HER2-mutant NSCLC balances route of administration, efficacy data by mutation subtype, and ...
Although it may take time for physicians to become used to this regimen, there is greater urgency now that it can be given ...
Antibody-drug conjugates (ADCs) have emerged as the primary solution for patients who have progressed on EGFR inhibitors and ...
Distinct Biology Driving Different Treatment Needs: Advances in genomic profiling reveal that pediatric leukemias are ...
Amandeep Salhotra, MD, discusses preclinical findings that could support the addition of a BCL2 inhibitor to address acute or ...
Dr Roberto Borea explores how BMI impacts NSCLC survival and molecular pathways, revealing key T-cell and redox data for IO ...
FDA‑approved zongepanib transforms HER2‑mutant NSCLC, delivering ~77% responses with less toxicity than chemo.
FDA cleared once-daily ruxolitinib XR for MF, HU-refractory/intolerant PV, and steroid-refractory acute/chronic GVHD after ...
Allogeneic HSCT is frequently complicated by acute GVHD (~50%) and chronic GVHD (30%–70%), with steroid-refractory disease representing a major unmet need despite ruxolitinib availability. CK0802 ...
Sabari, MD, discusses the depth and durability of response to zongertinib in patients with HER2 mutation–positive non–small ...
As advanced therapies continue to move beyond academic medical centers, the success of this transition will increasingly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results